Smi's 9th annual Imaging in Cancer Drug Development event
REGISTER BY 7TH DECEMBER AND RECEIVE A £300 DISCOUNTREGISTER BY 18TH JANUARY AND RECEIVE A £200 DISCOUNT SMi present their 9th annual conference on... Imaging in Cancer Drug Development Clinical Application and Innovation 13th and 14th March 2013, Copthorne Tara Hotel, London, UK KEY SPEAKERS INCLUDE: Anthony Giamis Prash Krishna Head of Radiochemistry Director – Oncology Clinical Development Abbott Eisai Peter Eggleton Yanping Luo Medical Director Oncology Group Leader, Translational Imaging Merck Abbott Werner Scheuer Kevin Brindle Research Leader Preclinical Imaging; Professor of Biomedical Magnetic Pharma Research and Early Development Resonance Roche Cambridge University Francois Lasailly Laura Kenny In-vivo Imaging Specialist Clinical Senior Lecturer/Consultant in Cancer Research UK Medical Oncology Imperial College Albert Windhorst Head of Radiopharmaceutical Chemistry Janos Kriston-Vizi VU University Group Leader of Bioinformatics Image Core Medical Research Council Erik Arstad Senior Lecturer in Radiochemistry Teng Jin Ong UCL Global Clinical Leader in Oncology Bayer KEY TOPICS FOR 2013: • Latest developments in fluorescence and bioluminescence for drug monitoring in xenografts Sponsored by • Novel target identification and lead discovery in preclinical biomarkers and radiochemistry • Strengths and limitations of whole body optical imaging with X-ray micro CT and multiphoton intravital microscopy • Overcoming challenges in nuclear tracers for multiscale imaging in oncology • Current application of PET/SPET modalities and a review of PFS (progression-free survival) • Practical tools for business expansion in the current economic climate PLUS INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOP Tuesday 12th March 2013, Copthorne Tara, London, UK Development of radiopharmaceuticals for PET Imaging in Oncology Workshop Leader: Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU University 13.00 – 17.00 To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737, email firstname.lastname@example.org or visit www.smi-online.co.uk/ts07.asp to register online
Imaging in Cancer Drug Development 2013Day One | Wednesday 13th March 2013 www.smi-online.co.uk/ts07.asp08.30 Registration and Coffee CURRENT ROLE OF IMAGING MODALITIES09.00 Chairmans Opening Remarks 13.40 Watching tumours gasp and die with MRI Peter Eggleton, Medical Director Oncology, Merck • Early detection of treatment response - why and how • Imaging tumour metabolism with hyperpolarised 13C-labelled cell09.10 Application of in vivo and ex vivo imaging in the drug development substrates process: monitoring primary tumor growth, metastasis and • Detecting drug response angiogenesis • Detecting tumour cell death • Application of fluorescence and bioluminescence for drug • Imaging the tumour microenvironment monitoring in xenografts Kevin Brindle, Professor of Biomedical Magnetic Resonance, • Monitoring primary tumor growth, metastasis and angiogenesis Cambridge University • Simultaneous measurement of pharmacodynamics and pharmacokinetics 14.20 Current role of PET/CT in cancer imaging – hybrid imaging improves • Future aspects (Cerenkov and hybrid systems) Werner Scheuer, Principle Optical Imaging, Roche the assessment of bone metastasis • The skeleton is a common site for metastases and newer treatment09.50 Novel advances in molecular imaging using the PhotonIMAGER are under investigation OPTIMA system • Bone metastases are usually considered “non-measurable” • Novel targets • Hybrid imaging provides new insight in the assessment of bone • Compare and contrast analogues metastases • Challenges faced with novel targets Yong Du, Consultant in Nuclear Medicine and PET/CT, Royal Marsden • Future developments Hospital Nicolas Carvou, Application Scientist, Biospace Lab 15.00 Afternoon Tea10.30 Morning Refreshments QUANTITIVE STUDIES & CHANGING PERSPECTIVES PRE-CLINICAL & CLINICAL IMAGING 15.30 Quantitative in vivo imaging of disease and response to therapy11.00 Non-invasive imaging of pre-clinical models for basic translational • Promise and peril of in vivo imaging research • FRAP of eCadherin to study EMT • Whole body optical imaging (bioluminescence and NIR fluorescence), • Sub-cellular targeting of Rho X-ray micro CT and multiphoton intravital microscopy • Spatial and temporal dynamics of Src response • Strengths and limitations Kurt Anderson, Oncology Team Leader, The Beatson Institute for • Ongoing developments Cancer Research Francois Lasailly, In-vivo Imaging Specialist, Cancer Research UK11.40 Overcoming chemical challenges in radiotracer development 16.10 Independent Radiological Committe (IRC) review for PFS - revisited • Synthesis of dual optical and nuclear tracers for multiscale imaging • IRC and its role in oncology drug development • Preparation of functional nanoparticles for imaging with SPECT • IRC versus Inv led Reviews and MRI • Changing Perspectives • One-pot ‘click-labelling’ of chemically labile precursors Prash Krishna, Director – Oncology, Clinical Development, Eisai • 18F aromatic labelling of ‘drug-like’ tracers Erik Arstad, Senior Lecturer in Radiochemistry, UCL 16.50 Chairman’s closing remarks12.20 Networking Lunch 17.00 Close of day one To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737 email email@example.com or visit www.smi-online.co.uk/ts07.asp to register online Sponsored by SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising Biospace Lab’s range of instruments is dedicated to small and branding packages, uniquely tailored to complement your company’s marketing animal preclinical imaging. strategy. Prime networking opportunities exist to entertain, enhance and expand your Biospace Lab has developed a comprehensive portfolio of client base within the context of an independent discussion specific to your ex vivo, in vivo and now in actio imaging solutions; which industry. Should you wish to join the are used by almost every major pharmaceutical company increasing number of companies benefiting from sponsoring our conferences please call: and prestigious academic research institutes worldwide. Alia Malick on +44 (0) 20 7827 6168 or www.biospacelab.com email: firstname.lastname@example.orgSupported by
www.smi-online.co.uk/ts07.asp Day Two | Thursday 14th March 20138.30 Re-registration and Coffee 12.10 Improving medical imaging diagnoses • High quality display and graphics for improved diagnostic abilities09.00 Chairmans Opening Remarks and patient treatment Anthony Giamis, Head of Radiochemistry, Abbott • Explore advancements in diagnoses solutions • Developments in software platforms for imaging in cancer drug IMAGING BIOMARKERS IN CANCER DRUG DEVELOPMENT discovery09.10 PET/SPECT imaging biomarker development • Innovative multi-display technology – increase number of reviews • Target identification and lead finding per day • Radiochemistry aspects Yanping Luo, Group Leader, Translational Imaging, Abbott • Preclinical evaluation • Translation towards clinic 12.50 Networking Lunch Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU University 14.20 Imaging modalities in drug discovery: high-content screening of a09.50 The importance of efficient early detection and diagnosis kinase inhibitor small molecule library to identify autophagy regulators • Observing tumor location(s), tumor-associated neoangiogenesis, • Imaging modalities incorporating kinase inhibitors suppression of antitumor immunity and visualising expression • Identifying autophagy regulators • Activity of specific molecules and biological processes that influence • Challenges faced in HTS of kinase inhibitors tumor behaviour and response to therapy • Future developments • Impact on cancer detection, metastases classification, individualized treatment, and drug development Janos Kriston-Vizi, Group Leader of Bioinformatics Image Core, • Bioluminescence and photoacoustic imaging applications Medical Research Council Teng Jin Ong, Global Clinical Leader in Oncology, Bayer 15.10 Afternoon Tea10.30 Biomarkers as predictors of therapeutic efficacy • Image-guided therapeutic delivery - development of novel cancer FUTURE OF IMAGING IN CANCER DRUG DEVELOPMENT imaging probes and biomarkers for screening, detection, diagnosis • Utilization of biomarkers for effective patient enrolment and proficient exchange of treatment paradigms – financial savings in the 15.50 Outmanagement for imaging experts in cancer drug development pharmaceutical industry • Practical tools for survival and growth during a period of • Role of imaging biomarkers in distinguishing metastases – efficient retrenchment prognosis • Expansion of medical imaging products in the market • Biomarkers and individualised medicine • Managing practical issues associated with oncology imaging Laura Kenny, Clinical Senior Lecturer/Consultant in Medical Oncology, • Standardization and development of proficiency in the field Imperial College Peter Eggleton, Medical Director Oncology, Merck11.00 Morning Refreshments 16.30 The pricing and reimbursement environment IMPROVING SUCCESS OF IMAGING MODALITIES • Key changes to payers willingness to pay • The cost containment programmes in key markets11.30 Molecular imaging innovation: PET/SPECT imaging in translational • How to ‘prove’ Value science Brian Lovatt, CEO, Vision Healthcare • Choosing a Target or Mechanism • Preparation of Radiotracer • Imaging Translation 17.10 Chairman’s closing remarks • Outcome and Assessments Anthony Giamis, Head of Radiochemistry, Abbott Laboratories 17.20 Close of day two To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737 email email@example.com or visit www.smi-online.co.uk/ts07.asp to register onlineWho should attend this conference:You should attend this event if you are a Director, Area Head, Chief Executive, Chief Scientific Want to know how you canOfficer, Vice President, Heads, Principal Scientist or Manager within the Pharmaceutical or get involved? Interested inHealthcare industry with responsibilities in the following areas: promoting your pharmaceutical• Imaging and • PET Research • Computer-Aided Drug • Medical Imaging services to this market? Translational Medicine • Biomarkers Design • Clinical Pharmacology Contact Kellee Halliburton,• Molecular Imaging • Target Discovery • Computational • Biophysics SMi Marketing• Cancer Research • Pharmacokinetics/ Chemistry • Screening on +44 (0) 207 827 6194, or• Oncology Pharmacodynamics • Structure and • Clinical Development email firstname.lastname@example.org• Pre-clinical Imaging • Drug Discovery & Informatics • Structural Biology• Clinical Imaging Design • Molecular Interaction
HALF-DAY PRE-CONFERENCE WORKSHOP Tuesday 12th March 2013 13.00 – 17.00 Copthorne Tara Hotel, London, UK Development of radiopharmaceuticals for PET Imaging in Oncology In association with VU University Workshop Leader: Albert Windhorst, Head of Radiopharmaceutical Chemistry, VU UniversityOverview of workshop:This workshop will be a unique interactive sessionwhere attendees can explore the development ofradiopharmaceuticals for PET Imaging in Oncology,alongside emerging ideas and case studies that can beapplied to their own roles and environments. Led by theexpertise and experience of Albert Windhorst, of VUUniversity, the workshop will explore the treatment ofpatients early in their disease process and facilitate theunderstanding of unmet needs in cancer drugdevelopment and oncology imaging.Overview of workshop:• Discover the benefits of developing radiopharmaceuticals for PET Imaging in oncology research• Address and overcome the key challenges associated with developing radiopharmaceuticals for PET Imaging• Evaluate past experiences and case studies and benefit from lessons learnt• Engage in an interactive session with a unique platform for discussionWorkshop Agenda:13.00 Registration and coffee13.30 Welcome & Introductions13.40 Route from conceptual idea to human application of a PET radiopharmaceutical • Identify biological targets for imaging • Identify lead compounds for radiopharmaceutical development14.15 Small molecule PET tracer development and monoclonal antibody PET tracers • Nuclides and radiochemistry • Considerations for development15.15 Afternoon Break15.30 Translation from preclinical research to clinical research • Animal experiments and typical studies • GMP production and legislation16.30 Discussion Session17.00 Close of WorkshopAbout the workshop hostDr Windhorst currently holds a position as associateprofessor in radiopharmaceutical chemistry at the VUUniversity Medical Center, where he heads theradiopharmaceutical chemistry section of thedepartment of Nuclear Medicine & PET Research. Hismain research interest is in the development andproduction of 11C and 18F radiolabeled compounds forclinical PET imaging, both research as for routineapplications.He is member of the board of the NKRV, EANM DrugDevelopment committee, president elect of the SRS,chairman of the 19th International Symposium onRadiopharmaceutical Chemistry, member of thescientific advisory board of the Journal LabeledCompounds and Radiopharmaceuticals and of CurrentRadiopharmaceuticals.About VU UniversityResearch at VU University Amsterdam covers a widerange of fields that often cut across disciplinaryboundaries. Within the Radionuclide Centre (RNC)scientific research with radioactive material isperformed. The RNC has facilities for all kinds ofchemical, biological and medical research withRadionuclides at Type-2-level.
SMI PHARMACEUTICALFORWARD PLANNER 2013 JANUARY Biomarkers Summit 16 – 17 January 2013, London Social Media in the Pharma Industry 23 – 24 January 2013, London Quality by Design 23 – 24 January 2013, London Pre-Filled Syringes 28 – 29 January 2013, London Pharmaceutical Microbiology 30 – 31 January 2013, London FEBRUARY Parallel Trade 6 – 7 February 2013, LondonAdvances and Progress in Drug Design 18 – 19 February 2013, London Lyophilisation - Freeze Drying in Pharmaceuticals and Biopharmaceuticals 25 – 26 February 2013, London MARCHSuperbugs & Superdrugs - A Focus on Antibacterials 4 – 5 March 2013, LondonImaging in Cancer Drug Development 13 – 14 March 2013, London Controlled Release 18 – 19 March 2013, London Paediatric Clinical Trials 20 – 21 March 2013, London APRIL Adaptive Designs 8 – 9 April 2013, London Asthma & COPD 15 – 16 April 2013, London Pharmaceutical Portfolio & Lifecycle Management 17 – 18 April 2013, London MAY Generics, Supergenerics & Patent Strategies 13 – 14 May 2013, London Pain Therapeutics 20 – 21 May 2013, London ADC Summit 20 – 21 May 2013, London Clinical Trial Logistics 22 – 23 May 2013, London JUNE RNAi & Nanotechnology 5 – 6 June 2013, London
IMAGING IN CANCER DRUG DEVELOPMENT Conference: Wednesday 13th and Thursday 14th March 2013, Copthorne Tara Hotel, London, UK Workshop: Tuesday 12th March 2013, London 4 WAYS TO REGISTER ONLINE at www.smi-online.co.uk/ts07.aspFAX your booking form to +44 (0) 20 7827 6737 POST your booking form to: Cem Tuna, SMi Group Ltd, 2nd Floor South,PHONE on +44 (0) 20 7827 6736 Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD □ Book by 7th December to receive a £300 off the conference price DISCOUNT □ Book by 18th January to receive a £200 off the conference price CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference & Workshop £2098.00 + VAT £2517.60 □ Conference only £1499.00 + VAT £1798.80Unique Reference Number □ Workshop only £599.00 + VAT £718.80Our Reference LVP-060 ts PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotionalDELEGATE DETAILS literature to all conference attendees £999.00 + VAT £1198.80Please complete fully and clearly in capital letters. Please photocopy for additional delegates.Title: Forename: GROUP DISCOUNTS AVAILABLESurname:Job Title: The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.Department/Division:Company/Organisation:Email: VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SRCompany VAT Number:Address: □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: email@example.com or fax +44 (0) 870 9090 712Town/City:Post/Zip Code: Country: DOCUMENTATIONDirect Tel: Direct Fax: I cannot attend but would like to purchase access to the following DocumentMobile: Portal/paper copy documentation Price TotalSwitchboard: □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80Signature: Date: □ The Conference Presentations – paper copy £499.00 - £499.00I agree to be bound by SMis Terms and Conditions of Booking. (or only £300 if ordered with the Document Portal)ACCOUNTS DEPTTitle: Forename: PAYMENTSurname: Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-060 and the delegate’s name. Bookings made withinEmail: 7 days of the event require payment on booking, methods of payment are below. PleaseAddress (if different from above): indicate method of payment: □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AUTown/City: Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18Post/Zip Code: Country: □ Cheque We can only accept Sterling cheques drawn on a UK bank.Direct Tel: Direct Fax: □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.Terms and Conditions of Booking Card No: □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□Payment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then credit carddetails will be requested and payment taken before entry to the event. Bookings within 7 days of CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX cardevent require payment on booking. Access to the Document Portal will not be given until paymenthas been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates may Cardholder’s Name:not ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a Signature: Date:substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, I agree to be bound by SMis Terms and Conditions of Booking.providing that cancellation is made in writing and received at least 28 days prior to the start of theevent. Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unable to Card Billing Address (If different from above):attend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other VATproducts and services. Unless you tick here □ we may also share your data with third partiesoffering complementary products or services. If you have any queries or want to update any of the VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Documentdata that we hold then please contact our Database Manager firstname.lastname@example.org visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your Portal and Literature Distribution for all UK customers and for those EU customers not supplyingaddress on the attached letter. a registration number for their own country here: ______________________________________ If you have NOT received registration confirmation within 48 hours of registering, please call +44 (0) 20 7827 6736